Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCL: Fully Automated Dual-hormone Artificial Pancreas in Type 1 Diabetes
NCT05199714Completed
- Sponsor
- McGill University Health Centre
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of pramlintide in type 1 diabetes mellitus (T1D) (5 arms), sponsored by McGill University Health Centre. Primary endpoint: Percentage of time glucose levels spent in the target range at 42 hours. Started Feb 2022; status: completed.
02
Drugs
pramlintide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05199714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199714.